$Gain Therapeutics(GANX.US)$NEWS
Gain Therapeutics Announces Positive Results from the Single Ascending Dose (SAD) Part of the Phase 1 Clinical Trial of GT-02287, a Novel GCase-Targeting Small Molecule Therapy for GBA1 Parkinson’s Disease
Positive results from the SAD part of the Phase 1 Clinical Trial of GT-02287.
GT-02287 was well tolerated with no serious adverse events.
Achieved appropriate plasma exposure levels after oral administration.
GT-02287 has the potential to slow or stop Parkinso...